Clinical Trial Update: Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer

View source ↗

Summary

This clinical trial update shows Kuopio University Hospital is recruiting for a Lutetium-177-PSMA study in PSMA PET-positive metastatic prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Lutetium-177 PSMA-617 (lutetium Lu-177 PSMA-617)

Snippet

Sponsor: Kuopio University Hospital | Conditions: Metastatic Prostate Adenocarcinoma, PSMA PET-Positive Castration-Resistant Prostate Cancer | Status: RECRUITING